Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Friday, October 16, 3:47 AM
| This Slide: #241 of 672 |
Slide #241. Spero Therapeutics, Inc. — Preferred Stock Offering
| Company: | Spero Therapeutics, Inc. (NASDAQ:SPRO) |
| Date announced: | 7/9/2018 |
| Shares Offered: | 3,780,000 |
| Date of Pricing: | 7/12/2018 |
| Price Per Share: | $12.50 |
| Preferred Stock Offering Details: | Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, today announced that it has commenced an underwritten public offering of 4,500,000 shares of its common stock. All of the shares in the offering will be sold by Spero. In addition, Spero expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price, less the underwriting discount. -updated 7/12- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the pricing of an underwritten public offering of 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock. The public offering price of each share of common stock is $12.50 and the public offering price of each share of Series A Preferred Stock is $12,500.00. The gross proceeds to Spero from this offering are $75,000,000, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Spero. All of the shares in the offering will be sold by Spero. In addition, Spero has granted the underwriters a 30-day option to purchase up to an additional 567,000 shares of common stock at the public offering price, less the underwriting discount. The offering is expected to close on July 17, 2018, subject to customary closing conditions. |
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206.
Open the SPRO Page at Preferred Stock Channel »
|
||||||||||||
|
|
Open the SPRO Page at Preferred Stock Channel (in a new window) »
|
Browse preferred stock yield screens, safer-income pages, offerings research, valuation and liquidation-preference screens, and related market idea pages from across the channel network. These links are grouped by topic to make the list easier to scan. Preferred Yield and Income ScreensCore PreferredStockChannel pages focused on high-yield preferreds, socially responsible income ideas, and safer-income preferred research. Offerings, Structure, and Screening ToolsPages for recent preferred offerings, preferreds by index membership or industry, and insider-related screening ideas. Premium, Discount, and Relative Value ScreensPages centered on preferred stock pricing relative to liquidation preference and comparative value signals. Dividend and Cross-Network Income ResearchRelated dividend and income pages from across the network that support preferred-stock investors comparing income vehicles. Analyst and Broader Market ResearchBroader analyst and market pages that remain part of the live homepage inventory. |
|
|
